MENU
+Compare
RARE
Stock ticker: NASDAQ
AS OF
Jan 17 closing price
Price
$40.00
Change
-$0.85 (-2.08%)
Capitalization
3.69B

RARE Ultragenyx Pharmaceutical Forecast, Technical & Fundamental Analysis

a developer of therapeutics for rare diseases

Industry Biotechnology
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for RARE with price predictions
Jan 08, 2025

RARE in -2.65% downward trend, declining for three consecutive days on January 02, 2025

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where RARE declined for three days, in of 318 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on January 08, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on RARE as a result. In of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The 50-day moving average for RARE moved below the 200-day moving average on January 03, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where RARE's RSI Oscillator exited the oversold zone, of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 63 cases where RARE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for RARE just turned positive on January 07, 2025. Looking at past instances where RARE's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RARE advanced for three days, in of 291 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.650) is normal, around the industry mean (14.746). P/E Ratio (0.000) is within average values for comparable stocks, (88.252). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.853). RARE has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (6.649) is also within normal values, averaging (264.084).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. RARE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RARE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

RARE is expected to report earnings to fall 4.29% to -134 cents per share on February 13

Ultragenyx Pharmaceutical RARE Stock Earnings Reports
Q4'24
Est.
$-1.34
Q3'24
Beat
by $0.08
Q2'24
Beat
by $0.14
Q1'24
Missed
by $0.28
Q4'23
Beat
by $0.18
The last earnings report on November 05 showed earnings per share of -139 cents, beating the estimate of -148 cents. With 795.09K shares outstanding, the current market capitalization sits at 3.69B.
A.I. Advisor
published General Information

General Information

a developer of therapeutics for rare diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
60 Leveroni Court
Phone
+1 415 483-8800
Employees
1276
Web
https://www.ultragenyx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AIWEX15.790.16
+1.02%
Cavanal Hill World Energy Institutional
ISIVX19.410.19
+0.99%
Voya US Stock Index Port A
RLEFX34.970.22
+0.63%
American Funds American Balanced R5E
TIEUX13.250.05
+0.38%
Morgan Stanley Pathway Intl Eq
MASFX10.820.02
+0.19%
iMGP Alt Strats Instl

RARE and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, RARE has been loosely correlated with VCYT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if RARE jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RARE
1D Price
Change %
RARE100%
-2.08%
VCYT - RARE
46%
Loosely correlated
-1.27%
DNLI - RARE
41%
Loosely correlated
+1.20%
CRNX - RARE
40%
Loosely correlated
+2.38%
ROIV - RARE
40%
Loosely correlated
+2.39%
XENE - RARE
38%
Loosely correlated
-2.78%
More